The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
about
Dimethyl sulfoxide promotes the multiple functions of the tumor suppressor HLJ1 through activator protein-1 activation in NSCLC cellsCytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells.Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitroOrganometallic anticancer compoundsImpact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin.Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment.Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.Neutron activation increases activity of ruthenium-based complexes and induces cell death in glioma cells independent of p53 tumor suppressor gene.Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications.Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549).Synthesis, DNA binding, hemolysis assays and anticancer studies of copper(II), nickel(II) and iron(III) complexes of a pyrazoline-based ligand.Anticancer activity of hydrogen-bond-stabilized half-sandwich Ru(II) complexes with heterocycles.The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems.EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.Reactivity of hexanuclear ruthenium metallaprisms towards nucleotides and a DNA decamer.Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies.The Spectroscopic and Conductive Properties of Ru(II) Complexes with Potential Anticancer PropertiesAnticancer metallodrugs of glutamic acid sulphonamides: in silico, DNA binding, hemolysis and anticancer studiesCopper(II), nickel(II), and ruthenium(III) complexes of an oxopyrrolidine-based heterocyclic ligand as anticancer agentsKinetics and mechanistic investigation into the possible activation of imidazolium trans-[tetrachloridodimethylsulfoxideimidazoleruthenate(iii)], NAMI-A, by 2-mercaptoethane sulfonate
P2860
Q28482396-35845CE6-20DA-4876-8F66-F18B34AC1C70Q33848447-0CD47810-D898-47A3-89B5-1413220DE26EQ33955538-7D8DCDD6-4BF6-4925-AA7D-02B69931467FQ34476685-2629F3D3-84FA-42EF-9CDF-E8AF1E3770F2Q35621511-200BFA4B-010C-4152-821D-35FF99AD0169Q36253687-C40CDCA9-96BA-48A6-ABE7-55C39829AC5FQ36287265-6DCED703-F26A-47C1-8D93-259054D55CF8Q37703236-623A9F67-0A9C-4898-B467-7AE0B0CC978EQ37997361-9C6ED0E6-5626-42C4-9A19-ED8DBBCC11B5Q38835381-36C61F43-6C77-4D5C-AC9F-8EEC987B4018Q38930683-DD203986-C236-4ABD-8532-00E5F709AFEBQ38979908-D9472005-BA22-44CF-BBF9-180A6D695E9AQ39000197-F845FAD4-8DC3-4F3E-8E7A-2842957B1124Q39202622-2AE17C15-6BE7-4DF3-8210-B23184DAE70AQ39295179-CEA010F9-6137-439A-B9CB-588A5A5A6807Q39400527-094D3423-CE86-4604-826E-0EB50C4275ABQ40737623-1D8EA4B8-5059-4D31-BEE7-5DE23183F0C6Q40759010-35B77E02-5ED9-4650-8AFC-5BAB453B44DCQ43811304-153CE23F-DBE3-4329-A56C-03837C3263CCQ45835320-AFA5C9CE-739B-409F-8EE7-4C4F344C3ED6Q47667663-0A381A3D-E819-4683-B8C0-C6EC5A10862CQ59062348-23CE06F2-76D8-4F70-BD2D-AC8A1A7A41BEQ59150079-1E9D4CBF-F6FB-4E0D-8A91-F606F59234A8Q59150086-CA9F83D2-057C-4BC7-8103-E0549207B9BCQ59205403-84A92BB2-1FBA-40B1-8050-BF2807966561
P2860
The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
The hydrolysis of the anti-can ...... c activity: an NMR evaluation.
@ast
The hydrolysis of the anti-can ...... c activity: an NMR evaluation.
@en
type
label
The hydrolysis of the anti-can ...... c activity: an NMR evaluation.
@ast
The hydrolysis of the anti-can ...... c activity: an NMR evaluation.
@en
prefLabel
The hydrolysis of the anti-can ...... c activity: an NMR evaluation.
@ast
The hydrolysis of the anti-can ...... c activity: an NMR evaluation.
@en
P2093
P1476
The hydrolysis of the anti-can ...... c activity: an NMR evaluation.
@en
P2093
Anna C G Hotze
Enzo Alessio
Gianni Sava
Jaap G Haasnoot
Jan Reedijk
Karlijn van der Schilden
Marina Bacac
Sabrina Pacor
P304
P356
10.1016/J.JINORGBIO.2003.12.003
P577
2004-02-01T00:00:00Z